Pediatric MigrainePhase 3NCT04649242
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
A Phase 3 study testing Rimegepant/BHV3000 in people with Pediatric Migraine, run by Pfizer at 246 sites in 9 countries.
Trial summary
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents. Read more about this study
- Who is it for?
- Ages 6 to 17 years
- Conditions the study is for
- Pediatric Migraine
- What is being tested?
- Rimegepant/BHV3000
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 2,100 participants
- Where
- 246 sitesin 9 countries
- Study dates
- 15 Jan 2021to 9 Jan 2029
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- History of migraine (with or without aura) for > 6 months before Screening according to the IHS Classification ICHD-319 specifications for pediatric migraine. History may be verified using both medical records and recall by the participant and/or participant's parent(s)/legal representative(s).
- History of 1 to 8 moderate or severe attacks per month during the 2 months prior to enrollment, with attacks lasting > 3 hours without treatment, and attacks occurring at intervals > 24 hours.
- Prophylactic migraine medication are permitted if the dose has been stable for at least 12 weeks prior to the Baseline Visit, and the dose is not expected to change during the course of the study.
- Participants may remain on one (1) medication with possible migraine prophylactic effects, excluding CGRP antagonists [biologic or small molecule], during the treatment phases.
- Concomitant use of a CGRP antagonist, such as erenumab or fremanezumab, is prohibited.
- Previously discontinued prophylactic migraine medication must have done so at least 90 days prior to the Screening Visit.
Show all 10Show fewer
- Verbally distinguish between migraine and other types of headaches.
- Participants must have a weight > 40 kg at the Screening Visit.
- Adequate venous access for blood sampling.
- Male and female participants ≥ 6 to < 18 years of age (participants must not reach their 18th birthday during the study).
Who cannot join
- History of cluster headache or hemiplegic migraine headache.
- Confounding and clinically significant pain syndrome that may interfere with the participant's ability to participate in this study.
- Current psychiatric condition that is uncontrolled and/or untreated for a minimum of 6 months prior to the Screening Visit. Participants with a lifetime history of psychosis and/or mania.
- History of suicidal behavior or major psychiatric disorder.
- Current diagnosis or history of substance abuse; positive drug test at Screening.
- History of moderate or severe head trauma or other neurological disorder (including seizure disorder) or systemic medical disease that is likely to affect central nervous system functioning.
Show all 10Show fewer
- Recent or planned surgery, requiring general anesthesia, <8 weeks prior to the Screening Visit.
- Participant has had gastrointestinal surgery that interferes with physiological absorption and motility (i.e., gastric bypass, duodenectomy, or gastric banding).
- Current diagnosis of viral hepatitis or a history of liver disease.
- Conditions considered clinically relevant in the context of the study such as uncontrolled hypertension (high blood pressure), diabetes, a life-threatening allergy
Trial locations and contacts
246 sites in 9 countries. Contact the study team or a site near you to ask about taking part.
246 sites in 9 countries
United States169 sites, 72 recruiting
- Active, not recruiting
Akron Children's Hospital
Akron, Ohio, 44308
- Recruiting
Dent Neurosciences Research Center
Amherst, New York, 14226
- Recruiting
Advanced Research Center, Inc.
Anaheim, California, 92805
- Recruiting
Michigan Head Pain & Neurological Institute
Ann Arbor, Michigan, 48104
- Active, not recruiting
Topaz Clinical Research, Inc.
Apopka, Florida, 32703
- Active, not recruiting
Children's Healthcare of Atlanta, Inc.
Atlanta, Georgia, 30329
- Active, not recruiting
Childrens Healthcare of Atlanta
Atlanta, Georgia, 30329
- Active, not recruiting
Rare Disease Research, LLC
Atlanta, Georgia, 30329
- Recruiting
Children's Hospital Colorado- lnvestigational Drug Services
Aurora, Colorado, 80045
- Recruiting
Children's Hospital Colorado
Aurora, Colorado, 80045
- Recruiting
Dell Children's Medical Center
Austin, Texas, 78723
- Active, not recruiting
Child Neurology Consultants of Austin - South Austin
Austin, Texas, 78749
- Active, not recruiting
Child Neurology Consultants of Austin - Central Austin
Austin, Texas, 78757
- Active, not recruiting
BioBehavioral Research of Austin
Austin, Texas, 78759
- Recruiting
Houston Clinical Trials, LLC
Bellaire, Texas, 77401
- Recruiting
Northwest Clinical Research Center
Bellevue, Washington, 98007
- Active, not recruiting
Achieve Clinical Research, LLC d/b/a Accel Research Sites-Neurology and Neurodiagnostic of Alabama
Birmingham, Alabama, 35244
- Active, not recruiting
Boston Clinical Trials
Boston, Massachusetts, 02131
- Active, not recruiting
Pivotal Clinical Research & Associates, LLC
Brunswick, Georgia, 31520
- Active, not recruiting
The University of Vermont Medical Center
Burlington, Vermont, 05401
- Active, not recruiting
New Hope Clinical Research
Charlotte, North Carolina, 28211
- Recruiting
OnSite Clinical Solutions, LLC
Charlotte, North Carolina, 28277
- Recruiting
Pediatric Associates of Charlottesville, PLC (Private Pediatric Practice)
Charlottesville, Virginia, 22902
- Recruiting
Pediatric Research of Charlottesville, LLC (Regulatory Only)
Charlottesville, Virginia, 22902
- Recruiting
Pediatric Research of Charlottesville, LLC
Charlottesville, Virginia, 22902
- Recruiting
Chicago Headache Center & Research Institute
Chicago, Illinois, 60657
- Recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229
- Active, not recruiting
Velocity Clinical Research
Cincinnati, Ohio, 45242
- Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106
- Active, not recruiting
Colorado Springs Neurological Associates, PC
Colorado Springs, Colorado, 80907
- Active, not recruiting
Colorado Springs Neurological Associates, PC
Colorado Springs, Colorado, 80919
- Active, not recruiting
Nationwide Children's Hospital
Columbus, Ohio, 43205
- Active, not recruiting
Wellnow Urgent Care and Research
Columbus, Ohio, 43228
- Recruiting
True North Neurology
Commack, New York, 11725
- Recruiting
Adult & Child Neurology Medical Associates
Costa Mesa, California, 92627
- Recruiting
CT Clinical Research
Cromwell, Connecticut, 06416
- Active, not recruiting
ProScience Research Group
Culver City, California, 90230
- Terminated
Beautiful Minds Clinical Research Center
Cutler Bay, Florida, 33157
- Active, not recruiting
Infinite Research Group, LLC
Dallas, Texas, 75201
- Active, not recruiting
Children's Medical Center, Dallas
Dallas, Texas, 75235
- Active, not recruiting
Children's Medical Center, Pediatric Anesthesiology Research (Study supplies only)
Dallas, Texas, 75235
- Active, not recruiting
Cedar Health Research
Dallas, Texas, 75251
- Recruiting
FutureSearch Trials of Dallas, LLC
Dallas, Texas, 75251
- Active, not recruiting
The University of Texas Southwestern Medical Center
Dallas, Texas, 75390
- Recruiting
CenExel iResearch, LLC
Decatur, Georgia, 30030
- Terminated
DeLand Clinical Research Unit
DeLand, Florida, 32720
- Recruiting
Velocity Clinical Research-Providence
East Greenwich, Rhode Island, 02818
- Recruiting
ANESC Research
El Paso, Texas, 79912
- Active, not recruiting
Eastside Therapeutic Resource, Inc. dba Core Clinical Research
Everett, Washington, 98201
- Recruiting
Precise Research Centers
Flowood, Mississippi, 39232
- Recruiting
Memorial Health Services
Fountain Valley, California, 92708
- Recruiting
Neuro-Pain Research Center
Fresno, California, 93710
- Active, not recruiting
North Texas Institute of Neurology and Headache
Frisco, Texas, 75034
- Active, not recruiting
Sarkis Clinical Trials
Gainesville, Florida, 32607
- Recruiting
Corewell Health, for and on behalf of Spectrum Health Hospital and Corewell Health Medical Group
Grand Rapids, Michigan, 49503
- Recruiting
Corewell Health, Helen DeVos Children's Hospital
Grand Rapids, Michigan, 49503
- Active, not recruiting
Velocity Clinical Research, Grants Pass
Grants Pass, Oregon, 97527
- Active, not recruiting
Boeson Research
Great Falls, Montana, 59405
- Recruiting
Northwell Health IRB
Great Neck, New York, 11021
- Active, not recruiting
Headache Wellness Center, PC
Greensboro, North Carolina, 27405
- Active, not recruiting
Premier Neurology, PC
Greenville, South Carolina, 29605
- Active, not recruiting
Tribe Clinical Research, LLC
Greenville, South Carolina, 29607
- Active, not recruiting
Velocity Clinical Research - Greenville
Greenville, South Carolina, 29615
- Active, not recruiting
Connecticut Children's Medical Center
Hartford, Connecticut, 06106
- Recruiting
UTHealth Houston
Houston, Texas, 77030
- Recruiting
Pain and Headache Centers of Texas
Houston, Texas, 77054
- Recruiting
SCLA Management
Houston, Texas, 77077
- Active, not recruiting
Houston Clinical Research,LLC.
Houston, Texas, 77081
- Recruiting
NeuroCare Plus
Houston, Texas, 77094
- Active, not recruiting
Wellnow Urgent Care and Research
Kalamazoo, Michigan, 49048
- Active, not recruiting
Boeson Research
Kalispell, Montana, 59901
- Active, not recruiting
Heart & Hands Midwifery
Kalispell, Montana, 59901
- Recruiting
Clinical Associates Midwest, LLC
Kansas City, Kansas, 66214
- Recruiting
Clinical Investigation Specialists, Inc
Kenosha, Wisconsin, 53144
- Active, not recruiting
Holston Medical Group.
Kingsport, Tennessee, 37660
- Active, not recruiting
Holston Medical Group
Kingsport, Tennessee, 37660
- Recruiting
Altman Clinical and Translational Research Institute, University of California San Diego
La Jolla, California, 92037
- Active, not recruiting
Multi-Specialty Research Associates, Inc.
Lake City, Florida, 32055
- Recruiting
Northwell Health Division of Pediatric Neurology Outpatient EEG Lab
Lake Success, New York, 11042
- Recruiting
Northwell Health/ Division of Pediatric Neurology
Lake Success, New York, 11042
- Terminated
Watson Clinic Center for Research, Inc.
Lakeland, Florida, 33805
- Terminated
Watson Clinic LLP
Lakeland, Florida, 33805
- Active, not recruiting
Kentucky Neuroscience Institute Child Neurology-- "Patients Seen"
Lexington, Kentucky, 40504
- Active, not recruiting
UK Center for Clinical and Translational Science (CCTS) -- "Patients Seen"
Lexington, Kentucky, 40536
- Active, not recruiting
University of Kentucky Hospital
Lexington, Kentucky, 40536
- Terminated
Alivation Research, LLC.
Lincoln, Nebraska, 68526
- Recruiting
Adult & Child Neurology Medical Associates
Long Beach, California, 90806
- Recruiting
Miller Children's & Women's Hospital Long Beach
Long Beach, California, 90806
- Active, not recruiting
National Research Institute
Los Angeles, California, 90057
- Recruiting
University Hospital
Madison, Wisconsin, 53792
- Active, not recruiting
Le Bonheur Children's Hospital - Outpatient Building
Memphis, Tennessee, 38103
- Active, not recruiting
Le Bonheur Children's Hospital
Memphis, Tennessee, 38103
- Active, not recruiting
Le Bonheur Childrens Hospital - Childrens Foundation Research Institute
Memphis, Tennessee, 38103
- Active, not recruiting
AppleMed Research Group, LLC
Miami, Florida, 33126
- Active, not recruiting
Medical Research Center of Miami II, Inc
Miami, Florida, 33134
- Recruiting
South Florida Research Phase I-IV, Inc
Miami, Florida, 33166
- Active, not recruiting
Brainstorm Research
Miami, Florida, 33176
- Active, not recruiting
NYU Langone Hospital-Long Island, Clinical Research Center
Mineola, New York, 11501
- Active, not recruiting
NYU Langone Hospital-Long Island, Pediatric Neurology
Mineola, New York, 11501
- Active, not recruiting
Blue Moose Pediatrics
Missoula, Montana, 59804
- Active, not recruiting
Boeson Research Laboratory
Missoula, Montana, 59804
- Active, not recruiting
Boeson Research
Missoula, Montana, 59804
- Recruiting
AMR-Baber Research Inc
Naperville, Illinois, 60563
- Active, not recruiting
Advanced Research for Health Improvement, LLC/ Dr. Cordero's Pediatric Office
Naples, Florida, 34102
- Recruiting
Aqualane Clinical Research
Naples, Florida, 34105
- Active, not recruiting
Access Clinical Trials, Inc.
Nashville, Tennessee, 37203
- Recruiting
HMH Jersey Shore University Medical Center
Neptune City, New Jersey, 07753
- Recruiting
HOPE Tower at Jersey Shore University Medical Center
Neptune City, New Jersey, 07753
- Active, not recruiting
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121
- Recruiting
New York Neurology Associates
New York, New York, 10003
- Recruiting
Weill Cornell Medicine
New York, New York, 10021
- Active, not recruiting
Mount Sinai Hospital - Pharmacy Department
New York, New York, 10029
- Active, not recruiting
Columbia University Medical Center Research Pharmacy
New York, New York, 10032
- Active, not recruiting
Columbia University Pediatric Neuromuscular Center
New York, New York, 10032
- Active, not recruiting
Irving Center for Clinical and Translational Research, Outpatient Clinical Research Unit
New York, New York, 10032
- Active, not recruiting
The Neurological Institute of New York
New York, New York, 10032
- Active, not recruiting
The Trustees of Columbia University and The New York and Presbyterian Hospital
New York, New York, 10032
- Recruiting
Children's Hospital of the King's Daughters
Norfolk, Virginia, 23507
- Recruiting
CHKD Health Center
Norfolk, Virginia, 23510
- Active, not recruiting
Neuro-Behavioral Clinical Research, Inc.
North Canton, Ohio, 44720
- Active, not recruiting
Velocity Clinical Research - North Hollywood
North Hollywood, California, 91606
- Active, not recruiting
IPS Research Company
Oklahoma City, Oklahoma, 73106
- Recruiting
Children's Hospital & Medical Center
Omaha, Nebraska, 68114
- Not yet recruiting
Children's Hospital of Orange County - Inpatient Pharmacy
Orange, California, 92868
- Not yet recruiting
Children's Hospital of Orange County - Neuroscience Center
Orange, California, 92868
- Not yet recruiting
Children's Hospital of Orange County
Orange, California, 92868
- Active, not recruiting
Coastal Clinical Research Specialists
Orange Park, Florida, 32073
- Recruiting
Clinical Associates of Orlando, LLC
Orlando, Florida, 32819
- Active, not recruiting
College Park Family Care Center Physicians Group- Neurology Research Dept.
Overland Park, Kansas, 66212
- Active, not recruiting
Sharlin Health Neuroscience Research Center
Ozark, Missouri, 65721
- Terminated
Bioresearch Institute
Pembroke Pines, Florida, 33026
- Recruiting
Clario
Philadelphia, Pennsylvania, 19103
- Active, not recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
- Active, not recruiting
AIM Trials, LLC
Plano, Texas, 75093
- Recruiting
The Neurology Group
Pomona, California, 91767
- Active, not recruiting
North Suffolk Neurology P.C
Port Jefferson Station, New York, 11776
- Recruiting
Providence Neuroscience Institute - Research Coordinator's Office
Portland, Oregon, 97225
- Recruiting
Providence St. Vincent Medical Center
Portland, Oregon, 97225
- Active, not recruiting
National Clinical Research, Inc.
Richmond, Virginia, 23294
- Recruiting
Brackenridge Outpatient Research Pharmacy
Rochester, Minnesota, 55905
- Recruiting
Clinical Research Trials Unit
Rochester, Minnesota, 55905
- Recruiting
Mayo Clinic
Rochester, Minnesota, 55905
- Terminated
Finger Lakes Clinical Research
Rochester, New York, 14618
- Active, not recruiting
Beaumont Hospital Royal Oak Campus
Royal Oak, Michigan, 48073
- Active, not recruiting
University of California, Davis Midtown Clinic
Sacramento, California, 95816
- Active, not recruiting
UC Davis Medical Center, Investigational Drug Service (IDS) Pharmacy
Sacramento, California, 95817
- Active, not recruiting
University of California, Davis Clinical and Translational Science Center Clinical Research (CCRC)
Sacramento, California, 95817
- Recruiting
JBR Clinical Research
Salt Lake City, Utah, 84107
- Recruiting
Wasatch Clinical Research , LLC(Administrative Location)
Salt Lake City, Utah, 84107
- Active, not recruiting
Velocity Clinical Research, San Bernardino
San Bernardino, California, 92408
- Recruiting
Perseverance Research Center, LLC
Scottsdale, Arizona, 85253
- Recruiting
Seattle Children's Hospital Investigational Drug Services
Seattle, Washington, 98105
- Recruiting
Seattle Children's Hospital
Seattle, Washington, 98105
- Active, not recruiting
Neurology and Headache Center, Inc.
Shreveport, Louisiana, 71105
- Recruiting
Velocity Clinical Research, Sioux City
Sioux City, Iowa, 51106
- Active, not recruiting
Clinvest Research, LLC
Springfield, Missouri, 65810
- Recruiting
Ki Health Partners, LLc, dba New England Institute for Clinical Research
Stamford, Connecticut, 06905
- Active, not recruiting
Forcare Clinical Research
Tampa, Florida, 33613
- Active, not recruiting
Physicians Research Group
Tempe, Arizona, 85284
- Terminated
Prime Global Research, LLC
The Bronx, New York, 10456
- Active, not recruiting
Lynn Institute of Tulsa
Tulsa, Oklahoma, 74135
- Active, not recruiting
Pacific Clinical Research Management Group LLC
Upland, California, 91786
- Recruiting
Sunwise Clinical Research
Walnut Creek, California, 94596
- Active, not recruiting
MedVadis Research Corporation
Waltham, Massachusetts, 02451
- Recruiting
Children's National Medical Center
Washington D.C., District of Columbia, 20010
- Recruiting
Integrated Clinical Trial Services
West Des Moines, Iowa, 50265
- Active, not recruiting
Premiere Research Institute at Palm Beach Neurology
West Palm Beach, Florida, 33407
- Recruiting
Options Research Group, LLC
Westfield, Indiana, 46074
- Active, not recruiting
Nemours Children's Hospital, Delaware
Wilmington, Delaware, 19803
China38 sites, 26 recruiting
- Active, not recruiting
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100089
- Active, not recruiting
First Affiliated Hospital of Bengbu Medical College Neurology
Bengbu, Anhui, 233000
- Recruiting
The First Hospital of Jilin University, Pediatric Neurology
Changchun, Jilin, 130021
- Recruiting
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410000
- Recruiting
Hunan Children's Hospital
Changsha, Hunan, 410007
- Recruiting
The Third Xiangya Hospital of Central South University
Changsha, Hunan, 410013
- Active, not recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041
- Recruiting
" The First Affiliated Hospital of Chongqing Medical University"
Chongqing, Chongqing Municipality, 400042
- Active, not recruiting
Hainan General Hospital
Haikou, Hainan, 571140
- Recruiting
Children's Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310052
- Recruiting
Anhui Provincial Hospital
Hefei, Anhui, 230000
- Recruiting
Shandong Provincial Qianfoshan Hospital
Jinan, Shandong, 250013
- Active, not recruiting
Jingzhou First People's Hospital
Jingzhou, Hubei, 434000
- Active, not recruiting
Lanzhou university second hospital
Lanzhou, Gansu, 730030
- Recruiting
The Second People's Hospital of Lianyungang
Lianyungang, Jiangsu, 222002
- Recruiting
Liaocheng People's Hospital
Liaocheng, Shandong, 252000
- Recruiting
Lu 'an People's Hospital
Lu'an
- Active, not recruiting
Ningbo Women and Children's Hospital
Ningbo, Zhejiang, 315012
- Active, not recruiting
Children's Hospital of Shanghai
Shanghai
- Recruiting
Shengjing Hospital of China Medical University
Shenyang
- Recruiting
Shenzhen Children's Hospital
Shenzhen, Guangdong, 518034
- Active, not recruiting
The First Affiliated Hospital of Shihezi University School of Medicine
Shihezi
- Recruiting
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000
- Recruiting
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050004
- Recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006
- Recruiting
The Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000
- Active, not recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022
- Recruiting
Renmin Hospital of Wuhan University
Wuhan, Hubei, 430060
- Recruiting
Wuhan Children's Hospital
Wuhan
- Recruiting
Wuxi Children's Hospital
Wuxi, Jiangsu, 214023
- Recruiting
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, 214115
- Active, not recruiting
Shaanxi Provincial People's Hospital
Xi'an, Shaanxi, 710068
- Active, not recruiting
Xi'an Gaoxin Hospital Neurology Department
Xi'an, Shaanxi, 710075
- Recruiting
Yan 'an University Xianyang Hospital
Xianyang, Shaanxi, 716000
- Recruiting
Xuzhou Children's Hospital
Xuzhou, Jiangsu, 221002
- Recruiting
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, 756000
- Recruiting
People's Hospital of Zhengzhou
Zhengzhou, Henan, 450000
- Recruiting
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, 212001
Japan13 sites, 12 recruiting
- Recruiting
Tennoji Dai Brain Clinic
Abeno-ku Osaka-shi, Osaka, 545-0053
- Recruiting
Konan Medical Center
Higashinada-ku Kobe-shi, Hyōgo, 658-0064
- Active, not recruiting
Local lndependent Administrative Corporation Hiroshima City Hospital Organization Hiroshima City
Hiroshima, 730-8518
- Recruiting
Tanaka Neurosurgery & Headache Clinic
Kagoshima, Kagoshima-ken, 890-0052
- Recruiting
Jinnouchi Neurosurgical Clinic
Kasuga-shi, Fukuoka, 816-0802
- Recruiting
Ikeda Neurosurgical Clinic
Kasuga-shi, Fukuoka, 816-0824
- Recruiting
Hikita Pediatric Clinic
Kiryu-shi, Gunma, 3760035
- Recruiting
Mito Kyodo General Hospital
Mito, Ibaraki, 310-0015
- Recruiting
Tominaga Clinic
Naniwa-ku, Osaka, 556-0015
- Recruiting
Yamaguchi Clinic
Nishinomiya-shi, Hyōgo, 663-8204
- Recruiting
Tokyo Headache Clinic
Shibuya-ku, Tokyo, 151-0051
- Recruiting
Tokyo Medical University Hospital
Shinjuku-ku, Tokyo, 160-0023
- Recruiting
Sendai Headache and Neurology Clinic
Taihaku-ku Sendai-shi, Miyagi, 982-0014
Poland8 sites, 6 recruiting
- Active, not recruiting
NZOZ Wielospecjalistyczna Poradnia Lekarska SYNAPSIS, Lech Szczechowski
Katowice, 40-123
- Recruiting
Centrum Medyczne Plejady
Krakow, 30-363
- Recruiting
Oddzial Kliniczny Dzieci Starszych z Pododdzialami: Neurologicznym, Reumatologicznym
Krakow, 31-503
- Recruiting
Wojewódzki Specjalistyczny Szpital Dzieciecy im. Sw. Ludwika w Krakowie, Apteka Szpitalna
Krakow, 31-503
- Recruiting
Wojewódzki Specjalistyczny Szpital Dzieciecy im. Sw. Ludwika w Krakowie
Krakow, 31-503
- Recruiting
Clinical Research Center Sp. z.o.o. Medic-R Spolka komandytowa
Poznan, 61-731
- Active, not recruiting
Euromedis Sp. z o. o.
Szczecin, 70-111
- Recruiting
MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak
Wroclaw, Lower Silesian Voivodeship, 52-210
Spain6 sites, 2 recruiting
- Recruiting
Hospital Universitario Vall d'Hebron
Barcelona, 08035
- Active, not recruiting
Centre d'Atencio Primaria Balenya
Barcelona, 08550
- Active, not recruiting
Instituto de Investigaciones del Sueno
Madrid, 28036
- Active, not recruiting
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, 39008
- Active, not recruiting
Hospital Universitario Virgen del Rocío
Seville, 41013
- Recruiting
Hospital Clinico Universitario de Valladolid
Valladolid, 47005
Mexico4 sites, 2 recruiting
- Active, not recruiting
Unidad de Investigacion en Salud de Chihuahua S.C.
Chihuahua City, 31203
- Recruiting
Clinstile S.A. de C.V.
Col. Roma Norte, Mexico City, C.P. 06700.
- Active, not recruiting
Neurociencias Estudios Clinicos S.C.
Culiacán, Sinaloa, 800200
- Recruiting
Clinical Reseach Institute, S.C.
Tlalnepantla, State of Mexico, C.P. 54055
Sweden3 sites, 2 recruiting
- Recruiting
ProbarE i Lund AB
Lund, Skåne LÄN [se-12], 22222
- Active, not recruiting
Avdelningen för kliniska Prövningar, Universitetssjukhuset Örebro
Örebro, 703 62
- Recruiting
ProbarE i Stockholm AB
Stockholm, 113 29
United Kingdom3 sites, 2 recruiting
- Active, not recruiting
Leicester Royal Infirmary
Leicester, LE1 5WW
- Recruiting
Re:Cognition Health Limited
London, W1G 8TA
- Recruiting
Great Ormond Street Hospital for Children NHS Foundation Trust
London, WC1N 3JH
Canada2 sites, 1 recruiting
- Recruiting
Kelowna Health & Memory Centre
Kelowna BC, British Columbia, V1Y 5A8
- Active, not recruiting
Diex Recherche Sherbrooke Inc
Sherbrooke, Quebec, J1L 0H8
About this study
Official title: Phase 3, Multicenter, Randomized, Double-blind, Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
- Conditions
- Pediatric Migraine
- Being tested
- Rimegepant/BHV3000, Matching placebo
- Keywords
- Migraine, Acute treatment, Phonophobia, Photophobia, Nausea, Pediatric, Children, Adolescent, Pediatric Migraine
- Medical subject headings
- Migraine Disorders, Hyperacusis, Photophobia, Nausea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Rimegepant/BHV3000Drug
BHV3000 (rimegepant) 75 mg or 50 mg ODT
Matching placeboDrug
Matching 75 mg or 50 mg ODT placebo
| Study group | Role | What they receive |
|---|---|---|
| BHV3000 (active drug) | Active comparator | BHV3000 (rimegepant) 75 mg or 50 mg ODT Receives: Drug: Rimegepant/BHV3000 |
| Placebo | Placebo comparator | Matching 75 mg or 50 mg ODT placebo Receives: Drug: Matching placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
To evaluate the efficacy of rimegepant compared with placebo in the acute treatment of migraine in adolescent population (≥ 12 to <18 years of age) as measured by pain freedom using the number of patients reporting no pain.
Pain freedom will be assessed in adolescent population (≥ 12 to < 18 years of age) on a 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe).
Measured: 2 hours post-dose
Secondary outcomes (16)
To compare rimegepant with placebo for pain freedom in children and adolescents combined.
Pain freedom will be assessed in children and adolescents (≥ 6 to < 18 years of age) using a 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe).
Pain freedom will be assessed in children (> 6 to < 12 years of age) using the 5-Face VAS (Face 5 = 'severe pain', Faces 4 and 3 = 'moderate pain', Face 2 = 'mild pain', Face 1 = 'no pain').
Measured: 2 hours post-dose
To compare rimegepant with placebo on freedom from the most bothersome symptom (MBS) associated with migraine in adolescents.
Freedom from MBS (nausea, phonophobia or photophobia) will be measured using a binary scale (0=absent, 1=present).
Measured: 2 hours post-dose
To compare rimegepant with placebo on the probabilities of requiring rescue medication within in adolescents.
Use of rescue medication will be assessed using the numbers of participants that take rescue medication.
Measured: Within 24 hours and 48 hours of initial treatment
To compare rimegepant with placebo on sustained pain freedom in adolescents.
Sustained pain freedom will be assessed using the number of participants that do not use any rescue medications and do not experience any headache pain post dose.
Measured: 2 to 24 hours post-dose
To compare rimegepant with placebo on sustained pain freedom in adolescents.
Sustained pain freedom will be assessed using the number of participants that do not use any rescue medications and do not experience any headache pain post dose.
Measured: 2 to 48 hours post-dose
To compare rimegepant with placebo on the ability to function normally as reported on the Functional Disability scale in adolescents.
The proportion of participants able to function normally will be assessed using the number that self-report as "normal" on the Functional Disability scale.
Measured: 2 hours post-dose
To compare rimegepant with placebo for pain freedom in children.
Pain freedom will be assessed using the number of children (≥ 6 to < 12 years of age) that report no pain measured by a 5-Face VAS (Face 5 = 'severe pain', Faces 4 and 3 = 'moderate pain', Face 2 = 'mild pain', Face 1 = 'no pain').
Measured: 2 hours post-dose
To compare rimegepant with placebo on freedom from the most bothersome symptom (MBS) associated with migraine in children and combined children and adolescents.
Freedom from the most bothersome symptom (nausea, phonophobia or photophobia) will be assessed using the number of participants that report the absence of MBS measured using a binary scale (0=absent, 1=present).
Measured: 2 hours post-dose
To compare rimegepant with placebo on the probabilities of requiring rescue medication in children and combined children and adolescents.
The probabilities of requiring rescue medication will be assessed using the numbers of participants that take rescue medication within initial treatment.
Measured: Within 24 hours and 48 hours of initial treatment.
To compare rimegepant with placebo on sustained pain freedom in children and combined children and adolescents.
Sustained pain freedom will be assessed using the number of participants that do not use any rescue medications and do not experience any headache pain post dose.
Measured: 2 to 24 hours post-dose
To compare rimegepant with placebo on sustained pain freedom in children and combined children and adolescents.
Sustained pain freedom will be assessed using the number of participants that do not use any rescue medications and do not experience any headache pain post dose.
Measured: 2 to 48 hours post-dose
To compare rimegepant with placebo on freedom from photophobia in adolescents, children and combined children and adolescents.
Freedom from photophobia will be assessed by the number of participants that report the absence of photophobia post dose that reported the presence of photophobia at baseline.
Measured: 2 hours post-dose
To compare rimegepant with placebo on freedom from phonophobia in adolescents, children and combined children and adolescents.
Freedom from phonophobia will be assessed by the number of participants that report the absence of phonophobia post dose that reported the presence of phonophobia at baseline.
Measured: 2 hours post-dose
To compare rimegepant with placebo on freedom from nausea in adolescents, children and combined children and adolescents.
Freedom from nausea will be assessed by the number of participants that report the absence of nausea post dose that reported the presence of nausea at baseline.
Measured: 2 hours post-dose
To compare rimegepant with placebo on pain relief in adolescents, children and combined children and adolescents.
Pain relief will be assessed using the number of participants that report a pain level of moderate or severe at baseline and then report a pain level of none or mild post dose.
Measured: 2 hours post-dose
To compare rimegepant with placebo in adolescents, children and combined children and adolescents on pain relief.
Time to first report of pain relief will be based on the first time point a participant reports a pain level of none or mild.
Measured: Time to patients first report of pain relief of none or mild post dose up to 48 hours.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2020
- Study start15 Jan 2021
- Primary completion9 Jan 2029 (estimated)
- Study completion9 Jan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pediatric MigraineStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 2,100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04649242
- Sponsor's protocol ID
- BHV3000-311
- Other IDs
- C4951002, 2020-003517-35, 2024-512743-23-00
- Status last verified
- Oct 2026
- First submitted
- 23 Nov 2020
- Last updated
- 27 Oct 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Study at a glance
From the registry record, last updated by the sponsor on 27 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase 3, Multicenter, Randomized, Double-blind, Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age
- ClinicalTrials.gov ID
- NCT04649242
- Acronym / sponsor ID
- BHV3000-311
- Conditions
- Pediatric Migraine
- Keywords
- Migraine, Acute treatment, Phonophobia, Photophobia, Nausea, Pediatric, Children, Adolescent
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 2,100 participants (estimated)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- 15 Jan 2021 (actual)
- Primary completion
- 9 Jan 2029 (estimated)
- Study completion
- 9 Jan 2029 (estimated)
- First posted
- 2 Dec 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| BHV3000 (active drug) | Active comparator | Drug: Rimegepant/BHV3000BHV3000 (rimegepant) 75 mg or 50 mg ODT |
| Placebo | Placebo comparator | Drug: Matching placeboMatching 75 mg or 50 mg ODT placebo |
Who may qualify
- Ages
- 6 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (10 listed)
- History of migraine (with or without aura) for > 6 months before Screening according to the IHS Classification ICHD-319 specifications for pediatric migraine. History may be verified using both medical records and recall by the participant and/or participant's parent(s)/legal representative(s).
- History of 1 to 8 moderate or severe attacks per month during the 2 months prior to enrollment, with attacks lasting > 3 hours without treatment, and attacks occurring at intervals > 24 hours.
- Prophylactic migraine medication are permitted if the dose has been stable for at least 12 weeks prior to the Baseline Visit, and the dose is not expected to change during the course of the study.
- Verbally distinguish between migraine and other types of headaches.
- Participants must have a weight > 40 kg at the Screening Visit.
Key exclusion criteria (10 listed)
- History of cluster headache or hemiplegic migraine headache.
- Confounding and clinically significant pain syndrome that may interfere with the participant's ability to participate in this study.
- Current psychiatric condition that is uncontrolled and/or untreated for a minimum of 6 months prior to the Screening Visit. Participants with a lifetime history of psychosis and/or mania.
- History of suicidal behavior or major psychiatric disorder.
- Current diagnosis or history of substance abuse; positive drug test at Screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Rimegepant/BHV3000BHV3000 (rimegepant) 75 mg or 50 mg ODT | Drug | BHV3000 (active drug) |
| Matching placeboMatching 75 mg or 50 mg ODT placebo | Drug | Placebo |
Primary outcome
To evaluate the efficacy of rimegepant compared with placebo in the acute treatment of migraine in adolescent population (≥ 12 to <18 years of age) as measured by pain freedom using the number of patients reporting no pain.
Time frame: 2 hours post-dose
Pain freedom will be assessed in adolescent population (≥ 12 to < 18 years of age) on a 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe).
16 secondary outcomes
To compare rimegepant with placebo for pain freedom in children and adolescents combined.
Time frame: 2 hours post-dose
To compare rimegepant with placebo on freedom from the most bothersome symptom (MBS) associated with migraine in adolescents.
Time frame: 2 hours post-dose
To compare rimegepant with placebo on the probabilities of requiring rescue medication within in adolescents.
Time frame: Within 24 hours and 48 hours of initial treatment
To compare rimegepant with placebo on sustained pain freedom in adolescents.
Time frame: 2 to 24 hours post-dose
To compare rimegepant with placebo on sustained pain freedom in adolescents.
Time frame: 2 to 48 hours post-dose
To compare rimegepant with placebo on the ability to function normally as reported on the Functional Disability scale in adolescents.
Time frame: 2 hours post-dose
To compare rimegepant with placebo for pain freedom in children.
Time frame: 2 hours post-dose
To compare rimegepant with placebo on freedom from the most bothersome symptom (MBS) associated with migraine in children and combined children and adolescents.
Time frame: 2 hours post-dose
To compare rimegepant with placebo on the probabilities of requiring rescue medication in children and combined children and adolescents.
Time frame: Within 24 hours and 48 hours of initial treatment.
To compare rimegepant with placebo on sustained pain freedom in children and combined children and adolescents.
Time frame: 2 to 24 hours post-dose
To compare rimegepant with placebo on sustained pain freedom in children and combined children and adolescents.
Time frame: 2 to 48 hours post-dose
To compare rimegepant with placebo on freedom from photophobia in adolescents, children and combined children and adolescents.
Time frame: 2 hours post-dose
To compare rimegepant with placebo on freedom from phonophobia in adolescents, children and combined children and adolescents.
Time frame: 2 hours post-dose
To compare rimegepant with placebo on freedom from nausea in adolescents, children and combined children and adolescents.
Time frame: 2 hours post-dose
To compare rimegepant with placebo on pain relief in adolescents, children and combined children and adolescents.
Time frame: 2 hours post-dose
To compare rimegepant with placebo in adolescents, children and combined children and adolescents on pain relief.
Time frame: Time to patients first report of pain relief of none or mild post dose up to 48 hours.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Oct 2026.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Related trials for Pediatric Migraine
RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Acute Treatment of Migraine
Not yet recruitingObservational study
Validation of the Vestibular Migraine Patient Assessment Tool and Handicap Inventory (VM-PATHI) for Adolescents
Vestibular Migraine
RecruitingPhase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
Episodic Migraine
RecruitingPhase 3
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Migraine
Active, not recruitingPhase 3
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
Migraine
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Pfizer CT.gov Call Center study director
Pfizer
246 sites in 9 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Rimegepant/BHV3000 in people with Pediatric Migraine, run by Pfizer at 246 sites in 9 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 246 sites in United States, China, Japan, Poland, Spain and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pfizer Pfizer CT.gov Call Center (1-800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To evaluate the efficacy of rimegepant compared with placebo in the acute treatment of migraine in adolescent population (≥ 12 to <18 years of age) as measured by pain freedom using the number of patients reporting no pain. (time frame: 2 hours post-dose). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.